Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Profile: Thomas Lönngren

Nature Biotechnology volume 22, page 1341 (2004)Cite this article

In his attempts to streamline the European Medicines Agency, Thomas Lönngren's style is one of evolution rather than revolution.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Dublin

    Sabine Louët

Authors
  1. Sabine Louët
    View author publications

    Search author on:PubMed Google Scholar

Related links

Related links

Related links in Nature Research

Biogenerics standoff

Betting on biogenerics

Biomanufacturing, from bust to boom...to bubble?

Rights and permissions

Reprints and permissions

About this article

Cite this article

Louët, S. Profile: Thomas Lönngren. Nat Biotechnol 22, 1341 (2004). https://doi.org/10.1038/nbt1104-1341

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt1104-1341

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing